Selinexor, Carfilzomib, and Dexamethasone in MM - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma image

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

Webinar
event Sep 07, 2022 / 01:00PM - 02:00PM EDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Hear from Dr. Craig Cole the results of the phase 1 study in 2019 with Selinexor, Carfilzomib and dexamethasone. How did this trial affect options for relapsed/refractory myeloma patients? What role does selinexor play in relapsed myeloma? Come with your questions about this trial and myeloma treatment.

Schedule & Agenda

The panelist Audrey Burton-Bethke
01:00 PM
Introduction
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Craig Cole.
The panelist Craig E. Cole, M.D.
01:05 PM
Presentation
Craig E. Cole, M.D.
Dr. Craig Cole talks about the results of the phase 1 study in 2019 with Selinexor, Carfilzomib and dexamethasone.
Event panelist Audience
01:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Craig E. Cole, M.D.
Craig E. Cole, M.D.

Craig Emmitt Cole, M.D. is a board-certified Hematologist who received his Bachelor of Science degree in physiology at Michigan State University and the College of Lyman Briggs, in East Lansing Michigan. Dr. Cole went on to receive his doctoral degree at the Ohio State University College of Medicine in Columbus, Ohio. He completed his Internal Medicine Residency and Hematology/Oncology Fellowship at the University of Michigan Health System, Ann Arbor, Michigan. Dr. Cole subsequently had a post-fellowship laboratory research position at the Jerome Lipper Multiple Myeloma Center of Medicine at Dana-Farber Cancer Institute in Boston, Massachusetts. This opportunity then led to him becoming an attending hematologist at Gundersen Health System in La Crosse, Wisconsin for 9 years. There he was an instructor for both the medical and nursing schools of the western campus of the University of Wisconsin School of Medicine and Public Health. He also served as Affiliate Faculty Member of Graduate Community Health Programs and Assistant Professor (Adjunct) at the University of Wisconsin-La Crosse, Department of Health Professions. While in Wisconsin, his clinical research interest was in multiple myeloma, malignant hematology, clinical apheresis, and patient reported outcomes in hematology. He then returned to the University of Michigan Rogel Cancer Center in Ann Arbor, Michigan as an Assistant Professor in the Division of Hematology/Oncology with his primary clinical and research interest being in multiple myeloma. In May of 2019, he returned to Michigan State University College of Human Medicine at Breslin Cancer Center as the Director of Clinical Research in Hematology/ Oncology and Multiple Myeloma. Dr. Cole has been participated in over 50 clinical trials in Multiple Myeloma and Malignant Hematology. He is a member of the International Myeloma Working Group, International Myeloma Society and the American Society of Hematology; he has published in national journals and presented at the American Society of Hematology International Myeloma Workshop, and the American Society for Apheresis meetings. He has lectured across the United States to patients, researchers and clinical providers in multiple myeloma, plasma cell dyscrasias, and disparities in cancer care. He has won awards for his work in student and resident teaching, multiple myeloma research, and patient advocacy. Dr. Cole has always had a strong commitment to equity of cancer care, patient empowerment, and community education by working with several local and national patient advocacy associations to bring the good news of myeloma research to everyone.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.